0001144204-19-044792.txt : 20190916 0001144204-19-044792.hdr.sgml : 20190916 20190916204758 ACCESSION NUMBER: 0001144204-19-044792 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190329 FILED AS OF DATE: 20190916 DATE AS OF CHANGE: 20190916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SQUINTO STEPHEN P CENTRAL INDEX KEY: 0001231954 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 191095863 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACEUTICALS INC STREET 2: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc. CENTRAL INDEX KEY: 0001773427 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-883-9490 MAIL ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 4 1 tv529540_form4.xml FORM 4 X0306 4 2019-03-29 0 0001773427 SpringWorks Therapeutics, Inc. SWTX 0001231954 SQUINTO STEPHEN P C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD. STAMFORD CT 06902 1 0 1 0 Stock Option (Right to Buy) 18.00 2019-09-12 4 A 0 29983 0 A 2029-09-12 Common Stock 29983 29983 D Series A Convertible Preferred Stock 2019-03-29 4 A 0 40000000 A Common Stock 6078103 6078103 I See footnote Series B Convertible Preferred Stock 2019-03-29 4 A 0 6931142 A Common Stock 1053204 1053204 I See footnote This option shall vest in equal monthly installments over the period of thirty six (36) months following September 12, 2019, subject to continued service to the Issuer on each vesting date. On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, OrbiMed Capital GP VI LLC ("GP VI") received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date. Shares held by GP VI. GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. On March 29, 2019, GP VI acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. /s/ Michael V. Greco as Attorney-in-Fact 2019-09-16